Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

Positive New Results of Tapinarof Cream Study for Pediatric Patients with AD
November 11, 2022

Dermavant announced positive results from its pediatric maximal usage study.

Eli Lilly Submits BLA for Lebrikizumab AD Treatment
November 09, 2022

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

FDA Accepts Phase 1 Clinical Trials of Exosome Therapy for AD
November 08, 2022

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Phase 2a Clinical Trial Enrollment for AD Passes Halfway Point
October 18, 2022

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

FDA Approves Dupliumab for Prurigo Nodularis
September 29, 2022

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions.

New Study Data of Roflumilast Foam for Scalp and Body Psoriasis
September 26, 2022

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.

Timber Pharmaceuticals Presents CI Study Data at EADV Congress
September 08, 2022

TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.

FDA Approves Spesolimab-Sbzo Injection for GPP Flares
September 02, 2022

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

Arcutis Finalizes Enrollment in Pivotal Phase 3 Trial of Roflumilast Cream for AD
August 25, 2022

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

FDA Accepts BLA for NexoBrid to Treat Severe Burns
August 19, 2022

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.